0001209191-20-013276.txt : 20200226 0001209191-20-013276.hdr.sgml : 20200226 20200226202901 ACCESSION NUMBER: 0001209191-20-013276 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200224 FILED AS OF DATE: 20200226 DATE AS OF CHANGE: 20200226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sarena Francis Willard CENTRAL INDEX KEY: 0001423786 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36070 FILM NUMBER: 20658028 MAIL ADDRESS: STREET 1: C/O FIVE PRIME THERAPEUTICS, INC. STREET 2: 2 CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001175505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260038620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-365-5600 MAIL ADDRESS: STREET 1: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: FIVE PRIME THERAPEUTICS INC DATE OF NAME CHANGE: 20020613 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-24 0 0001175505 FIVE PRIME THERAPEUTICS, INC. FPRX 0001423786 Sarena Francis Willard 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Strategy Officer Common Stock 2020-02-24 4 A 0 15000 0.00 A 93178 D Common Stock 2020-02-24 4 A 0 15000 0.00 A 108178 D Common Stock 2020-02-25 4 F 0 1863 4.87 D 106315 D Common Stock 2020-02-26 4 F 0 1304 4.83 D 105011 D Employee Stock Option (right to buy) 5.25 2020-02-24 4 A 0 90000 0.00 A 2030-02-23 Common Stock 90000 90000 D Employee Stock Option (right to buy) 5.25 2020-02-24 4 A 0 90000 0.00 A 2030-02-23 Common Stock 90000 90000 D Represents a retention equity incentive award consisting of shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 24, 2021, 2022 and 2023, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date. Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 24, 2021, 2022 and 2023, provided the reporting person provides services to the Company through each such date. Represents a retention equity incentive award consisting of options to purchase shares of the Company's common stock. One-fourth (1/4) of the shares underlying this option will vest on February 24, 2021, and the remainder of the shares underlying this option vest at a rate of one forty-eighth (1/48) per month thereafter, provided the reporting person provides services to the Company through each such date. The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 24, 2020, provided the reporting person provides services to the Company through each such date. /s/ Francis Sarena 2020-02-26